Evolocumab Is Mainly Prescribed In Fh Patients With/Without Atherosclerotic Cardiovascular Disease (Ascvd) In Lipid/Internal Medicine Units In Spain: A Retrospective …

Abstract:

Methods: Retrospective, observational, chart review of consecutive patients initiating evolocumab (Feb-2016 to Jul-2017), in 20 Spanish Internal Medicine Units. Patient characteristics, lipid modifying drugs and lipid profiles over time were retrospectivelly collected at 12 weeks pre-and 12±4 weeks post-evolocumab initiation. Results: 136 patients were enrolled: 64.0% men; mean (SD) age, 56.6 (11.5) years; mean body mass index, 29.4 (4.8) kg/m2. 75.0%(n= 102) had FH (2.9% homozygous, 64.0% heterozygous, 8.1% undetermined FH); 36.8% were FH in primary prevention; 48.5% started evolocumab after previous ASCVD. Other CV risk factors were: hypertension (43.4%), diabetes (18.4%), and smoking (17.6%); 36.0% were statin intolerant. At evolocumab initiation, 61.0% of patients were on a high intensity statin and 60.3% were receiving ezetimibe. Mean (SD) LDL-C at evolocumab initiation was 169.1 (56.6 …

Año de publicación:

2019

Keywords:

Fuente:

google